Pfizer Accused of Deception on Neurontin | Newsweek Health

Stem-Cell Breakthrough
Anne Underwood 7/24/2009 12:00:00 AM
It's a chilling thought. In the coming year, 130,000 people worldwide will suffer spinal-cord injuries—in a car crash, perhaps, or a fall. More than 90 percent of them will endure at least partial paralysis. There is no cure. But after a decade of hype and controversy over research on embryonic stem cells—cells that could, among other things, potentially repair injured spinal cords—the world's first clinical trial is about to begin. As early as this month, the first of 10 newly injured Americans, paralyzed from the waist down, will become participants in a study to assess the safety of a conservative, low-dose treatment. If all goes well, researchers will have taken a promising step toward a goal that once would have been considered a miracle—to help the lame walk.
The Next Blockbuster Drugs
7/22/2009 12:00:00 AM
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market.
THE VERDICT | Dahlia Lithwick
When Judges Behave Badly
Dahlia Lithwick 2/28/2009 12:00:00 AM
February was a spectacularly bad month for the judging business. Last week Samuel Kent, a federal district judge in Texas, pleaded guilty to obstruction-of-justice charges in exchange for the state's dropping sex-crime charges. Kent may go to prison for three years for groping female subordinates, and there is talk in the Senate of his impeachment. Then Sharon Keller, presiding judge of the Texas Court of Criminal Appeals, was charged by her state's Commission on Judicial Conduct with five counts of violating her duty and discrediting the court.
CAREERS
Job Killers
1/30/2009 12:00:00 AM
Continuing jobless claims rose by 159,000 in the week ended Jan. 17 to a seasonally adjusted 4.78 million, the most since the government's records began in 1967. The number of unemployed people in the US could rise by one million this month, almost twice the figure for December.
Dean Ornish - The Spectrum
The Garbage Trucks in Your Blood
12/18/2006 12:00:00 AM
Medicine Man
Richard M. Smith
When Pfizer's board chose a new CEO last summer, it passed over two 30-year Pfizer veterans to pick vice chairman and general counsel Jeff Kindler, who joined the company in 2002 after stints at General Electric and McDonald's. In the latest in his series of interviews as part of the NEWSWEEK-Kaplan M.B.A. program, NEWSWEEK Chairman and Editor-in-Chief Richard M. Smith spoke with Kindler about reinvigorating Pfizer.